U.S. Transportation Stock News

The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...

As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...

TowneBank ( NASDAQ:TOWN ) shareholders (or potential shareholders) will be happy to see that insider J. Perry recently...

Stanley Black & Decker (SWK) just delivered a first quarter that topped its own expectations, reaffirmed its full year outlook and used Aerospace Fasteners sale proceeds for debt reduction and a new US$500 million buyback. See our latest analysis for Stanley Black & Decker. The stock has been choppy over shorter periods, with a 14.41% 1 month share price return and a 2.69% year to date share price return. However, a 36.98% 1 year total shareholder return suggests momentum has recently...

At its April 17, 2026 Technology Open Day, Hesai Group unveiled its Picasso 6D full-color lidar chip and ETX lidar series, which combine geometry and color sensing on a single ASIC and are targeted for L3-plus autonomous driving with mass production planned in the second half of 2026. The move into a broader “spatial intelligence” platform, spanning automotive, robotics, and embodied AI, positions Hesai to supply sensing hardware across a wide range of future Physical AI applications. We’ll...

In April 2026, Charles River Laboratories International launched an enhanced in vitro fertility (IVF) service bundle for rat models, combining embryo transfer, cryopreservation, and colony rederivation to help research teams accelerate preclinical programs across oncology, neurology, cardiology, and metabolic disease while easing breeding bottlenecks. This IVF expansion deepens the company’s Genetically Engineered Model Services offering, highlighting how specialized reproductive...

In late April 2026, Arlo Technologies reported Q4 2025 results that surpassed analyst expectations on earnings per share and revenue, while its CFO Kurtis Joseph Binder sold US$146,077 of stock under a pre-arranged Rule 10b5-1 plan. At the same time, Arlo’s Board authorized a US$50 million share repurchase program through December 31, 2027, signaling management’s confidence in the company’s outlook even as insiders have been net sellers in recent months. Next, we’ll examine how Arlo’s...

BeOne Medicines (ONC) has drawn fresh attention after the FDA granted Priority Review to a supplemental Biologics License Application for TEVIMBRA with ZIIHERA and chemotherapy in advanced HER2-positive gastroesophageal cancers, alongside a global HH160 collaboration. See our latest analysis for BeOne Medicines. Despite the FDA Priority Review for TEVIMBRA and the new HH160 collaboration, the share price return has softened recently. The 30-day share price return is 5.45% and the 90-day share...

Recent performance snapshot for GRAIL (GRAL) GRAIL (GRAL) has traded around US$54.06 at the latest close, with the stock showing a 1 day return of about a 1% decline and a 7 day return of roughly a 2% decline. Over the past month, the stock’s return is near a 2% decline, while the past 3 months show a deeper move of about a 49% decline, setting a very different picture from its reported 1 year total return of about 58%. See our latest analysis for GRAIL. The recent share price weakness,...

nLIGHT, Inc. recently announced it will expand its existing operations in Torino, Italy, to boost local assembly, integration, testing, and lifecycle support for high-power directed energy laser subsystems serving European and allied defense customers. This move deepens nLIGHT’s role in NATO-aligned defense programs by emphasizing localization, secure supply chains, and closer collaboration with European system integrators and research partners. We’ll now examine how this Torino expansion,...

Kite Realty Group Trust recently reported first-quarter 2026 results showing revenue of US$200.7 million and net income of US$11.39 million, with diluted EPS of US$0.06, alongside full-year 2026 EPS guidance of US$0.33–US$0.39 and an affirmed quarterly dividend of US$0.29 per share. Beneath softer headline earnings, the REIT delivered 3.6% same-property NOI growth, executed over 700,000 square feet of leasing, and repurchased 6 million shares for about US$152 million, highlighting...

Ryder System’s board recently declared a regular quarterly cash dividend of US$0.91 per share to be paid on June 19, 2026, and authorized a new share repurchase plan of up to 2.0 million shares running through May 1, 2028. These moves, alongside first-quarter earnings that prompted higher full-year 2026 EPS guidance, underline management’s emphasis on disciplined capital deployment and shareholder returns supported by a largely contract-based business model. With Ryder increasing its 2026...

Glass, a GovTech company, has entered Mastercard Start Path’s inaugural Corporate Solutions program to enhance digital payment infrastructure for the public sector. This collaboration aims to modernize government transactions by providing scalable solutions that improve efficiency, transparency, and intelligence in public finance. As part of a select group of fintech companies, Glass gains access to Mastercard’s extensive network, fostering innovation and opportunities within the global...

As you might know, Broadridge Financial Solutions, Inc. ( NYSE:BR ) just kicked off its latest third-quarter results...

Why Oppenheimer Holdings (OPY) Is On Investors’ Radar Today Oppenheimer Holdings (OPY) has caught investor attention after a recent stretch of mixed short term trading, with the stock showing a 7 day decline alongside gains over the past month and past 3 months. That contrast, combined with a last close of $106.81 and a market value around $1.14b, is prompting some investors to reassess how this middle market investment bank and broker dealer fits into their portfolios. See our latest...

In April 2026, Eastern Bankshares, Inc. reported first-quarter 2026 net income of US$65.3 million, reversing a prior-year net loss, while also detailing reduced net loan charge-offs of US$9.7 million, a quarterly dividend increase to US$0.15 per share, and completion of US$130.49 million in share repurchases under its October 2025 program. This combination of a return to profitability, higher cash returns to shareholders, and active buybacks highlights management’s focus on capital...

In the first quarter of 2026, PROCEPT BioRobotics reported revenue of US$83.13 million, up from US$69.16 million a year earlier, while its net loss widened to US$31.64 million and basic loss per share from continuing operations increased to US$0.56. Alongside this growth, the company reinforced the clinical and commercial appeal of its Aquablation therapy through stronger European guideline support, AI software clearance for its HYDROS system, and reaffirmed full-year 2026 revenue...

Mattel, Inc. reported past first-quarter 2026 results with net sales rising to US$862.2 million and net income improving to US$61 million, alongside ongoing share repurchases under two completed buyback authorizations. Beyond the headline beat, Mattel is leaning into an IP- and digital-focused model, committing US$150 million in 2026 to expand brands like Hot Wheels, UNO, and Monster High across entertainment and gaming. We’ll now examine how Mattel’s earnings beat and raised full-year EPS...

At its April 29, 2026 annual meeting, Pool Corporation’s stockholders elected Mark A. Pompa as director, while the board approved a 4% increase in the quarterly cash dividend to US$1.30 per share, payable on May 28, 2026 to stockholders of record on May 14, 2026. Released alongside first-quarter 2026 results that showed higher sales and largely unchanged earnings, the dividend increase highlights management’s willingness to return more cash to shareholders even as performance remains steady...

Key earnings snapshot and what triggered the move Artisan Partners Asset Management (APAM) is back on investors’ radar after first quarter results combined higher revenue with lower profit, significant net outflows from equity strategies, and a jump in credit and alternatives inflows. The company reported revenue of US$303 million for the quarter, compared with US$277.1 million a year earlier. Net income was US$58 million versus US$61.1 million, with basic and diluted EPS from continuing...

Recent analyst actions on Lennar (LEN), including lowered price targets from Evercore ISI and Wells Fargo alongside fresh second quarter 2026 forecasts, have sharpened attention on how guidance and sentiment are shaping the stock’s current pricing. See our latest analysis for Lennar. The recent 1-day share price return of 2.05% decline and 7-day share price return of 5.15% decline sit alongside a 90-day share price return of 21.40% decline and 1-year total shareholder return of 17.51%...

Recent performance snapshot for Dover (DOV) Dover (DOV) has traded quietly in the short term, with a small 1 day and week return decline, while showing a gain over the past month, past 3 months and year to date. See our latest analysis for Dover. At a share price of $225.79, Dover’s recent 30 day share price return of 9.94% and year to date gain of 15.35%, alongside a 1 year total shareholder return of 31.92%, point to building momentum and improving sentiment around its growth and risk...

In late April 2026, Rollins, Inc. reported first-quarter net income of US$107.84 million, affirmed its US$0.1825 per-share quarterly dividend, and filed an omnibus shelf registration covering common and preferred stock, debt securities, and various equity-linked instruments. Investor interest was further shaped by Polen Capital adding Rollins to its Focus Growth Strategy, citing the company’s resilient pest-control business model, disciplined acquisitions such as Saela Pest Control, and...

Rhythm Pharmaceuticals recently announced that the European Commission expanded marketing authorization for IMCIVREE (setmelanotide) to treat obesity and control hunger in adults and children aged 4 and above with acquired hypothalamic obesity due to hypothalamic injury or impairment, based on Phase 3 TRANSCEND trial data showing a placebo-adjusted reduction in body mass index. This twin US and EU approval for acquired hypothalamic obesity meaningfully broadens IMCIVREE’s addressable patient...